Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.82 |
| ▸ | THPO | P40225 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N6-Benzyladenosine SCHEMBL13966412 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL20419317 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL15614834 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL472637 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL472635 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL23982413 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL20419282 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL3283829 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL219439 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL30230333 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117338801-A | Application of N6-substituted adenosine derivative or N6-substituted purine derivative in preparation of medicine for relieving peri-operative neuroinflammation | 河北医科大学 | 2024-01-05 | — | — | CN | claimed |
| EP-4292426-A1 | JUVENILE BAMBOO PLANT OF THE GENUS FARGESIA | Plant Select NV (BE) | 2023-12-20 | — | — | EP | claimed |
| CN-104382924-A | N6-substituted adenosine derivative and N6-substituted adenine derivative and application thereof | INST MATERIA MEDICA CAMS | 2015-03-04 | — | — | CN | claimed |
| EP-1671616-B1 | Hair growth promoter composition | LION CORP (JP) | 2012-02-29 | — | — | EP | claimed |
| US-8119614-B2 | Substitution derivatives of N6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2012-02-21 | — | — | US | claimed |
| EP-2339912-A2 | HYBRID PEPPER PLANTS RESULTING FROM A CROSS BETWEEN C.ANNUUM AN D C.PUBESCENS | Seminis Vegetable Seeds, Inc. (US) | 2011-07-06 | — | — | EP | claimed |
| WO-2010025297-A2 | HYBRID PEPPER PLANTS RESULTING FROM A CROSS BETWEEN C. ANNUUM AND C. PUBESCENS | SEMINIS VEGETABLE SEEDS, INC. (US) | 2010-03-04 | — | — | WO | claimed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | claimed |
| EP-1575973-A2 | SUBSTITUTION DERIVATIVES OF N SP 6 SP -BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2005-09-21 | — | — | EP | claimed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| WO-2004058791-A2 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2004-07-15 | — | — | WO | claimed |
| US-6168952-B1 | REGENERATING PLANTS FROM RHIZOME IN MEDIUM, ROOT EXCISION, CULTURING IN MEDIUM CONTAINING LOW NITROGEN AND ENHANCED PHOSPHOROUS CONTENT AND 6-BENZYLADENINE | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2001-01-02 | — | — | US | claimed |
| EP-4747386-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | Bisirna Therapeutics Pte. Ltd. (SG) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743089-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH OCRL GENE DISFUNCTION | Fondazione Telethon ETS (IT) | 2026-05-20 | — | — | EP | disclosed |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2026-04-30 | — | — | US | disclosed |
| EP-0504279-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. | CHEMGEN CORP (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991009130-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| EP-0355825-A2 | Viral treatment system | Prendergast, Patrick T. (IE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0322242-A2 | Adenosine derivatives | GLAXO GROUP LIMITED (GB) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | ADORA3 162/4885SLC29A1 710/4885TP53 2033/4885 |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA2B, ADORA3, ADORA2A | ADORA3 2/4885SLC29A1 299/4885TP53 400/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | ADORA3 153/4885SLC29A1 670/4885TP53 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.